Clinical Trials
6 trialsNCT05533775 2026-06-03
iMATRIX GLO
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05583617 2026-06-03
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT04524871 2026-05-22
MORPHEUS-LIVER
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT03564340 2026-05-08
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT04691817 2026-01-07
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Abramson Cancer Center at Penn Medicine
Phase 1/2 Recruiting